About the Authors
- Kirill Litovkin
-
Contributed equally to this work with: Kirill Litovkin, Aleyde Van Eynde
Affiliation Laboratory of Biosignaling & Therapeutics, KU Leuven Department of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium
- Aleyde Van Eynde
-
Contributed equally to this work with: Kirill Litovkin, Aleyde Van Eynde
* E-mail: Aleyde.VanEynde@med.kuleuven.be
Affiliation Laboratory of Biosignaling & Therapeutics, KU Leuven Department of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium
- Steven Joniau
-
Affiliation Urology, University Hospitals Leuven & KU Leuven Department of Development and Regeneration, University of Leuven, Leuven, Belgium
- Evelyne Lerut
-
Affiliation Pathology, University Hospitals Leuven & KU Leuven Department of Imaging and Pathology, University of Leuven, Leuven, Belgium
- Annouschka Laenen
-
Affiliation KU Leuven Biostatistics and Statistical Bioinformatics Centre, University of Leuven, Leuven, Belgium
- Thomas Gevaert
-
Affiliation Urology, University Hospitals Leuven & KU Leuven Department of Development and Regeneration, University of Leuven, Leuven, Belgium
- Olivier Gevaert
-
Affiliations Stanford Center for Cancer Systems Biology, Stanford University School of Medicine, Stanford, California, United States of America, Laboratory of Cancer Data Fusion, KU Leuven Department of Oncology, University of Leuven, Leuven, Belgium
- Martin Spahn
-
Affiliations Department of Urology, University Hospital Bern, Inselspital, Bern, Switzerland, Department of Urology and Paediatric Urology, University Hospital Würzburg, Würzburg, Germany
- Burkhard Kneitz
-
Affiliation Department of Urology and Paediatric Urology, University Hospital Würzburg, Würzburg, Germany
- Pierre Gramme
-
Affiliation DNAlytics SA, Chemin du Cyclotron 6, 1348 Louvain-la-Neuve, Belgium
- Thibault Helleputte
-
Affiliation DNAlytics SA, Chemin du Cyclotron 6, 1348 Louvain-la-Neuve, Belgium
- Sofie Isebaert
-
Affiliation Radiation Oncology, University Hospitals Leuven & KU Leuven Department of Oncology, University of Leuven, Leuven, Belgium
- Karin Haustermans
-
Affiliation Radiation Oncology, University Hospitals Leuven & KU Leuven Department of Oncology, University of Leuven, Leuven, Belgium
- Mathieu Bollen
-
Affiliation Laboratory of Biosignaling & Therapeutics, KU Leuven Department of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium
Competing Interests
A GB patent, entitled 'Marker gene based prognosis of prostate cancer', was filed in UK with priority date of January 27, 2014 (GB1401371.8), and with AVE, KL and MB as inventors. TH is the CEO and Pierre Gramme the principal analyst of DNAlytics, SA (Chemin du Cyclotron 6, 1348 Louvain-la-Neuve, Belgium). This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: AVE KL SJ MB. Performed the experiments: KL. Analyzed the data: KL AVE SJ AL TG OG PG TH MB. Contributed reagents/materials/analysis tools: EL MS BK SI. Wrote the paper: AVE KL SJ KH MB. Pathological analysis: EL.